OXFORD, England & TORONTO--(

牛津、英格兰和多伦多--(

BUSINESS WIRE

商业热线

)--

)--

Oxford Cancer Analytics (OXcan)

牛津癌症分析（OXcan）

, the medtech company developing blood tests for early cancer detection using advanced proteomics and AI, today announced it has raised US$11 million in Series A funding from global investors, including in-field institutional investors in disease detection and diagnostics. The funding round was led by .

，这家使用先进蛋白质组学和人工智能开发用于早期癌症检测的血液检测的medtech公司今天宣布，它已从全球投资者（包括疾病检测和诊断领域的现场机构投资者）的A系列融资中筹集了1100万美元。融资回合由领导。

We Venture Capital

我们风险投资

and

和

Cross-Border Impact Ventures

跨境冲击企业

with participation from return investors

回报投资者的参与

Eka Ventures

创业

, and

，以及

Civilization Ventures

文明创业

, and new investors

，以及新投资者

DigitalDx Ventures

Digital Dx Ventures

,

,

Macmillan Cancer Support

麦克米伦癌症支持

(Innovation Impact Investment Portfolio),

（创新影响投资组合），

Aurelium Ventures

Aurelium Ventures公司

,

,

OKG Capital

OKG资本

, and prominent angel investors. This investment positions the company to develop and globally commercialize its new generation of minimally invasive liquid biopsy blood tests for the

，以及著名的天使投资者。这项投资使该公司能够开发新一代微创液体活检血液测试并在全球范围内商业化

early detection of lung cancer

肺癌的早期发现

.

.

OXcan has also appointed

OXcan还任命

Dr. Heinrich Roder

Heinrich Roder博士

as Senior Vice President, Research & Development. With over two decades of experience in lung cancer liquid biopsy and commercialization, Dr. Roder will further advance OXcan’s lung cancer blood test for deployment.

担任研发部高级副总裁。凭借在肺癌液体活检和商业化方面20多年的经验，Roder博士将进一步推进OXcan肺癌血液检测的部署。

OXcan’s protein-based blood test identifies molecular signatures for high-risk lung cancer patients, leveraging a diverse global biobank to ensure worldwide scalability. Using advanced proteomics and AI, it fills an unmet niche in the liquid biopsy space by offering a protein-based blood test with high accuracy to detect cancers with the highest mortality burden..

OXcan基于蛋白质的血液测试可识别高危肺癌患者的分子特征，利用多样化的全球生物库确保全球可扩展性。使用先进的蛋白质组学和人工智能，它通过提供高精度的基于蛋白质的血液检测来检测死亡率最高的癌症，填补了液体活检领域未满足的利基。。

Since 2023, OXcan has formed global partnerships, collaborating with over 20 healthcare centers across three continents to develop and deploy its technology.

自2023年以来，OXcan与三大洲的20多个医疗保健中心建立了全球合作伙伴关系，共同开发和部署其技术。

About Oxford Cancer Analytics

关于牛津癌症分析

Oxford Cancer Analytics (OXcan) is on a mission to drastically transform cancer early detection and management to impact millions of lives worldwide. OXcan's multidisciplinary team is developing a new generation of liquid biopsy blood tests using cutting-edge proteomics and explainable machine learning approaches that can detect the deadliest cancers early, when they can still be cured.

牛津癌症分析公司（OXcan）的使命是彻底改变癌症的早期发现和管理，以影响全球数百万人的生命。OXcan的多学科团队正在开发新一代液体活检血液测试，使用先进的蛋白质组学和可解释的机器学习方法，可以在最致命的癌症仍然可以治愈的早期发现。

This blood test can be conducted in an affordable, minimally invasive, and routine manner with superior accuracy and localization capacity in large populations. OXcan has applied their biomarker discovery and validation platform starting from lung cancer, the leading cause of cancer mortality worldwide, and achieved ISO13485 certification status.

这种血液测试可以以负担得起的，微创的和常规的方式进行，在大量人群中具有更高的准确性和定位能力。OXcan已经从肺癌（全球癌症死亡率的主要原因）开始应用其生物标志物发现和验证平台，并取得了ISO13485认证状态。

For additional information, visit .

有关更多信息，请访问。

oxcan.org

oxcan.org

.

.